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■ Resumen
Antecedentes: Los efectos antiinfl amatorios de los ácidos grasos poliinsaturados n-3 (AGPI n-3) se han demostrado tanto in vivo como 
in vitro. Los resultados de estudios epidemiológicos realizados sugieren que el consumo de pescado tiene un efecto benefi cioso sobre la 
función pulmonar y la prevalencia del asma. No obstante, los datos obtenidos a partir de estudios clínicos de intervención no han revelado 
efectos benefi ciosos de la toma de suplementos AGPI n-3 en pacientes con la enfermedad establecida. 
Objetivo: Estudiar los efectos de la suplementación con AGPI n-3 a corto plazo combinado con la terapia de mantenimiento sobre el óxido 
nítrico espirado en pacientes asmáticos. 
Métodos: Se efectuó un estudio de doble ciego controlado con placebo en el que participaron 20 mujeres asmáticas. Se administró a las 
pacientes una combinación de ácido eicosapentaenoico y de ácido docosahexaenoico con 10 mg de vitamina E o placebo dos veces al 
día durante dos semanas. El principal criterio de valoración fue la fracción de óxido nítrico espirado (FeNO) y el secundario fue el control 
del asma (puntuación en el Cuestionario de control del asma [ACQ]) y la función pulmonar (volumen espiratorio forzado en el primer 
segundo [FEV1]). 
Resultados: No se observaron diferencias signifi cativas en el FeNO, la puntuación ACQ o el FEV1 entre las pacientes que tomaron suplementos 
de AGPI n-3 y las que tomaron el placebo.
Conclusiones: Los suplementos dietéticos a corto plazo con AGPI n-3 en mujeres con asma estable no se asociaron con cambios 
estadísticamente signifi cativos en los valores FeNO, de control del asma o de la función pulmonar.
Palabras clave: Asma. Infl amación de las vías respiratorias. Ácidos grasos poliinsaturados n-3. Ácido eicosapentaenoico. Ácido 
docosahexaenoico. Óxido nítrico espirado.
■ Abstract
Background: The anti-infl ammatory effects of n-3 polyunsaturated fatty acids (n-3 PUFA) have been demonstrated both in vitro and in vivo. The 
results of epidemiological studies suggest that fi sh consumption has a benefi cial effect on lung function and prevalence of asthma. However, 
data from intervention trials have not revealed a benefi cial effect of n-3 PUFA supplementation in patients with established disease.
Objective: To study the effects of short-term n-3 PUFA supplementation in addition to maintenance therapy on exhaled nitric oxide in 
asthmatic patients. 
Methods: A double-blind, placebo-controlled trial was undertaken in 20 women with asthma. Patients received either a combination of 
eicosapentaenoic acid and docosahexaenoic acid plus 10 mg vitamin E or placebo twice daily for 2 weeks. The primary outcome measure 
was the fraction of exhaled nitric oxide (FeNO) and the secondary outcomes were asthma control (score on the Asthma Control Questionnaire 
[ACQ]) and lung function (forced expiratory volume in 1 second [FEV1]). 
Results: No signifi cant differences were observed in FeNO, ACQ score, or FEV1 between patients receiving n-3 PUFA supplementation and 
those receiving placebo.
Conclusions: Short-term dietary supplementation with n-3 PUFA in women with stable asthma was not associated with statistically 
signifi cant changes in FeNO, asthma control, or lung function
Key words: Asthma. Airway infl ammation. n-3 Polyunsaturated fatty acids. Eicosapentaenoic acid. Docosahexaenoic acid. 
Exhaled nitric oxide.
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Introduction
There is currently a lack of consensus regarding the proposed 
association between reduced intake of n-3 polyunsaturated fatty 
acids (n-3 PUFA) and increased prevalence of allergic diseases 
[1-3]. Although preventive effects of n-3 PUFA supplementation 
in terms of allergic sensitization or infl ammatory variables have 
been reported [4-7], data generated from intervention trials have 
failed to show meaningful improvement in clinical or functional 
asthma outcomes once the disease is established [8].
The aim of this study was to determine whether airway 
infl ammation assessed by exhaled nitric oxide is improved 
by short-term dietary n-3 PUFA supplementation in stable 
asthmatic patients receiving inhaled corticosteroids. 
Methods
Subjects
Adult women diagnosed with stable persistent asthma who 
attended the allergy clinic of University Hospital São João 
were invited to participate. Stable asthma was defi ned as the 
absence of asthma exacerbations requiring oral prednisolone 
or an increased use of inhaled corticosteroids in the previous 
4 weeks, use of rescue medication no more than 3 times a 
week, and the absence of clinical indications for alteration 
of treatment. Persistent asthma was defi ned by current use of 
inhaled corticosteroids. Patients were excluded if they were 
smokers, took antileukotrienes, had any chronic diseases other 
than asthma and rhinitis, were pregnant, or if they did not 
take contraceptive measures. The study was approved by the 
hospital ethics committee.
Study Design
The study was a randomized, double-blind, placebo-
controlled trial. General data were collected at the screening visit. 
After enrollment, at the baseline visit, subjects were randomly 
assigned to the intervention. Capsules of n-3 PUFA or placebo 
were labeled with study numbers according to a prepared blocked 
randomization list. Patients were allocated study numbers 
sequentially and, thus, randomly allocated trial supplement. The 
n-3 PUFA group (n=11) received 2 fi sh-oil capsules (Coolmar, 
Biopura, Lisbon, Portugal) containing a combination of 455 
mg eicosapentaenoic acid (EPA) and 325 mg docosahexaenoic 
acid (DHA) plus 10 mg vitamin E each, taken once daily for 2 
weeks; the placebo group (n=9) received 2 capsules of amide 
daily for the same period. The fi nal visit was performed 3 days 
after the intervention. Compliance was monitored by counting 
returned capsules. 
Outcomes
The primary outcome measure was the fraction of exhaled 
nitric oxide (FeNO) and the secondary outcomes included 
lung function and control of asthma. FeNO was measured 
using the NIOX system (Aerocrine, Stockholm, Sweden) 
[9]. Asthma control was assessed using the 6-item Asthma 
Control Questionnaire (ACQ) [10]. The ACQ was developed 
to measure the adequacy of clinical asthma control with a score 
ranging from 0 (good) to 6 (poor). Forced expiratory volume 
in the fi rst second (FEV
1
) was determined by spirometry using 
a Vitalograph 2120 spirometer (Vitalograph Ltd, Buckingham, 
UK). A baseline Asthma Life Quality (ALQ) test [11] was 
administered. The ALQ test has a score ranging from 0 (good) 
to 20 (poor). Dietary intake was measured using a semi-
quantitative food frequency questionnaire (FFQ) administered 
by a nutritionist and analyzed using Food Processor Plus 
software (ESHA Research, Salem, USA). 
Statistical Analysis
Analysis was conducted on an intention-to-treat basis, with 
subjects defi ned as all randomized patients who took at least 1 
dose of the intervention. The estimated sample size required 
to detect a 33% effect of the intervention using FeNO as the 
main outcome was 20 subjects [12]. Clinical characteristics 
of placebo and n-3 PUFA groups were compared by Student t 
test for continuous variables and proportions were compared 
with χ2 tests. Comparisons between baseline and fi nal visits 
were made with paired t test. Comparisons between groups 
were made by covariance analysis.
The covariance analysis considers the initial value of the 
parameter as a covariate, allowing a better estimation of the 
effect of the intervention. Statistical signifi cance was set at 
P < .05.
 
Results
Of the 23 patients screened and randomized, 20 were 
analyzed (Table 1). Three withdrew before taking any 
supplement, having indicated that they were unable to 
attend visits. No side-effects, such as bleeding or menstrual 
problems, were reported. Patient compliance was above 
75% in all cases. No differences were observed between 
n-3 PUFA and placebo groups in terms of the change in 
FeNO (P = .373), FEV
1
 (P = .533), or ACQ score (P = .978) 
(Table 2). A signifi cant increase in FeNO was observed in 
the placebo group (P = .041) and an improvement in ACQ 
score was observed in the placebo (P = .033) and n-3 PUFA 
(P =.021) groups (fi gure).
Discussion
In asthma, FeNO is used as an indirect marker of airway 
infl ammation and is correlated with infl ammatory biomarkers 
such as blood eosinophils, IgE level, and allergic sensitization 
[15]. Elevated levels of FeNO result from increased expression 
and activity of the inducible nitric oxide synthase (iNOS) in 
airway epithelial and infl ammatory cells following stimulation 
by proinfl ammatory cytokines such as interleukin-1, tumor 
necrosis factor α, and interferon-γ [16,17]. However, the effects 
of n-3 PUFA on iNOS are unclear. In human osteoblastic cells, 
EPA prevented the increase in iNOS gene expression [18] 
while in rat vascular smooth muscle cells, DHA potentiated 
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  Table 2. Changes in Exhaled Nitric Oxide, Lung Function, and Asthma Control After Supplementation With n-3 PUFA Compared to Placebo*
 Placebo, n=9 n-3 PUFA, n=11†  Placebo 
      vs n3PUFA‡
  Baseline  Post Change† Baseline Post Change† P 
    intervention   intervention  
 F
E
NO, ppb  20.4 25.0 4.6  27.6  30.0  2.4  .373 
  (10.0 – 30.1) (12.3 – 37.7) (0.2 – 8.9);  (16.6 – 38.6) (15.8 – 44.2) (–3.5 – 8.3);  
    P = .041 P = .386
 FEV
1
, % 90.9  94.5  3.7    96.7   100.7   4.0  .533 
  (75.9 – 105.8) (75.9 – 113.0) (-4.6 – 12.9); (85.4 – 108.0) (87.9 – 113.6) (–3.7 – 11.7);
      P=.336 P = .276  
 ACQ score 1.7  1.1  -0.6   1.4   1.0 –0.5   ..978 
  (1.0 – 2.5) (0.4 – 1.8) (–1.2 – –0.1); (0.8 – 2.1) (0.4 – 1.5) (–0.9 – –0.1)
    P = .033 P = .021
  *Data are shown as means (95% confi dence interval). PUFA indicates polyunsaturated fatty acids; FENO, fractional exhaled nitric oxide; ppb, parts per 
  billion; FEV1, forced expiratory volume in 1  second; ACQ, asthma control questionnaire.
  †Paired samples t test; ‡Analysis of covariance, baseline value as covariate.
iNOS expression [19]. 
Because of the exploratory nature of our study, the 
number of patients could have been insuffi cient to establish 
statistical signifi cance. Additionally, duration or dosage of 
the supplement may have been inadequate to achieve the 
hypothesized antiinfl ammatory effects. Higher ratios of n-6:
n-3 PUFA have been associated with an increased risk of 
asthma [20]. However, our strategy—supplementation at a 
dose known to carry no risk of adverse events and over a 
short period of time—is more prone to increase compliance in 
real life. We restricted inclusion to women based on previous 
observations that the relationship between asthma measures 
and diet or obesity is sex dependent [21,22]. Almost all of the 
subjects were within the normal range for baseline FeNO, 
with values probably representing optimum FeNO levels, due 
to the current use of inhaled corticosteroids. It can be argued 
that the likelihood of a meaningful change would therefore be 
limited. However, the aim of our study was not to determine 
whether n-3 PUFA supplementation would be better than 
inhaled corticosteroids in terms of exhaled nitric oxide, but 
rather to assess if any further benefi t would appear from n-3 
PUFA supplementation in addition to regular maintenance 
treatment.
Previous studies failed to show any consistent effect of 
n-3 PUFA on FEV
1
. Doses from 200 to 3000 mg per day of 
EPA/DHA from 1 month to 1 year had no signifi cant effect on 
lung function [23-25], while in 2 studies, 10 to 20 g per day 
of perilla-seed oil for 1 month in 14 asthma patients [26] and 
Table 1. Baseline Characteristics of the Patient Group*
 
                      Placebo, n=9 n–3 PUFA, n=11 P
Age, y                      34 (24 – 44) 41 (37 – 46) .222
BMI, kg/m2 25 (19 – 31) 28 (20 – 36) .553
Atopic, n (%) 6 (66.7) 6 (54.5) .670
Inhaled corticosteroids, μg†  686 (274 – 1097)  1000 (486 – 1514) .251
PUFA n–6:n–3, mean ± SD 8.7 ± 2.6 10.1 ± 2.2 .252
FeNO, ppb 20.4 (10.0 – 30.1)    27.6 (16.6 – 38.6) .309
ACQ score 1.7 (1.0 – 2.5) 1.4 (0.8 – 2.1) .488 
FEV
1
, % predicted 90.9 (75.9 – 105.8) 96.7 (85.4 – 108.0) .478
AQL score 13.9 (11.6 – 16.2) 13.5 (10.9 – 16.2) .222  
*Data are shown as means (95% confi dence interval) unless otherwise indicated. FEV1 indicates forced expiratory volume in the fi rst second; ACQ, 
Asthma Control Questionnaire; AQL, Asthma Quality of Life questionnaire; FeNO: fraction of exhaled nitric oxide; PUFA, polyunsaturated fatty acids; 
BMI, body mass index. 
†Budesonide equivalent dose. Groups were compared by χ2 or t test where appropriate.
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1000 mg per day of EPA/DHA for 1 year in 12 asthma patients 
[27] improved FEV
1
. Seven of our patients had an FEV
1
 below 
80% of predicted and 5 had an ACQ score above 2, leaving 
little room for improvement in these measurements. 
In this pilot study, we failed to show any clinically 
meaningful or statistically signifi cant effect of n-3 PUFA 
supplementation in women with asthma. Trials involving larger 
numbers of subjects over a longer period of time are needed 
to fully assess the effect of EPA/DHA on asthma. 
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